期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

药物代谢酶细胞色素P4502C9研究进展 被引量：15

Advance of drug metabolism enzyme P450 2C9
下载PDF
导出
摘要 P4 5 0 2C9是人体中重要的药物代谢酶。P4 5 02C9基因编码区的多态性造成氨基酸序列的变化 ,主要包括P4 5 0 2C9 2和P4 5 0 2C9 3两种突变体 ,变异纯合子对P4 5 0 2C9底物的代谢能力明显降低。P4 5 0 2C9的底物包括甲苯磺丁脲、苯妥英、S 法华令、氟西汀、洛沙坦等。P4 5 0 2C9可被利福平诱导 。 P450 2C9 is the most important drug metabolizing enzymes in humans. Polymorphisms in P450 2C9 gene produce variants at amino acid including P450 2C9*2 and P450 2C9*3. Metabolic capacities for P450 2C9 substrates are diminished by individuals of homozygous. P450 2C9 substrates mainly include tolbutamide, phenytoin, S-warfarin, fluoxetine, and losartan. P450 2C9 can be induced by rifampin and inhibited by amiodarone and fluconazole.
作者 陈騉 王睿
机构地区 中国海洋大学 解放军总医院临床药理室
出处 《中国临床药理学与治疗学》 CAS CSCD 2004年第6期601-606,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家 8 63计划支持项目 (№ :2 0 0 2AA2Z3 41L)
关键词 细胞色素P450 2C9 基因多态性 药物代谢 遗传药理学 P450 2C9 genetic polymorphism drug metabolism pharmacogenetics
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献18

  • 1[1]Lee S, Kim JM, Chung CS, Cho K J, Kim JH. Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients[J]. Arch Pharm Res, 2003; 26 (11): 967 -72
  • 2[2]eSchwarz UI. Clinical relevance of genetic polymorphisrms in the human CYP2C9 gene[J]. Eur J Clin Invest, 2003;33(2) :23 -30
  • 3[3]Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic RA. Genetic polymorphisms of cytochromes P450: CYP2C9,CYP2C19, and CYP2D6 in Croatian population[J]. Croat Med J, 2003;44(4) :425 - 8
  • 4[4]Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations[J]. Fundam Clih Pharmacol,2003; 17(3) :373 - 6
  • 5[5]Takahashi H, WilkinsonGR, Caraco Y, Muszkat M, Kim RB,Kashima T, et al. Population diffcrenees in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients [J]. Clin Pharmacol Ther, 2003; 73 (3): 253 - 63
  • 6[6]Xie HG, Prasad HC, Kim RB, and Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance[J]. Adv Drug Deliv Rev, 2002;54(10): 1257 - 70
  • 7[7]Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP,Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian Populations[J]. Pharmacogenetics, 1997 ;7(2): 103 - 113
  • 8[8]Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA,Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin,glipizide and in an individual homozygous for the CYP2C9 * 3allele[J]. Pharmacogenetics, 1999: 9(1): 71 - 80
  • 9[9]Van der Weide J, Steijns LS, van Weelden MJ, de Haan K.The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement [J]. Pharmacogenetics, 2001; 11(4) :287 - 91
  • 10[10]Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J]. Clin Pharmacol Ther, 2002;72(6) :702 - 10

二级参考文献25

  • 11.Mechan RR, Gosden JR, Rout D, et al. Human cytochrome P450PB-1:A multigene family involved in mephenytoin and steroid oxidations that maps to human chromosome 10. Am J Hum Genet, 1988; 48: 26～37.
  • 22.Kimura S, Pastewka J, Gelboin HV, et al. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res, 1987; 15: 10053～10054.
  • 33.Vermeij P, Ferrari MD, Buruma OJ, et al. Inheritance of poor phenytoin parahydroxylation capacity in an Dutch family. Clin Pharmacol Ther, 1988; 44: 588～593.
  • 44.Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996; 6: 341～349.
  • 55.Brian WR, Srivastava PK, Umbenhauer DR, et al. Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemitry, 1989; 28: 4993～4999.
  • 66.Jones BC, Hawksworth G, Horne VA, et al. Putative active site template model for cytochrome P450 (tolbutamide hydroxylase). Drug Meta Dispo,1995; 24: 260～266.
  • 77.Miners JO, Rees DLP, Valenre L, et al. Human hepatic cytochrome P450 catalyzes the rate limiting pathway of torasemide metabolism. J Pharmacol Exp Ther, 1995; 272: 1076～1081.
  • 88.Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 1994; 4: 39～42.
  • 99.Vasco MR, Dell RD, Daly DD, et al. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther,1980; 27: 96～103.
  • 1010.Inaba T. Phenytoin: pharmacogenetic polymorphism of 4?hydroxylation.Pharmacol Ther, 1990; 46: 341～347.

共引文献19

同被引文献181

引证文献15

二级引证文献167

中国临床药理学与治疗学
2004年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部